MyTheragene®


Personalized pharmacotherapy based on human DNA.

Pharmacogenomics

MyTheragene®

Personalized pharmacotherapy based on human DNA
Pharmacogenomics is a rapidly evolving division of clinical pharmacology that deals with the research and study of genetically determined alterations that affect:

• metabolism (pharmacokinetics)
• the action (pharmacodynamics) of drugs in humans.

The proteins and enzymes that regulate each individual's response to drugs often show functional differences due to genetic background.
MyTheragene® is an innovative multi-gene test, with high sensitivity and specificity, which is based on pharmacogenomic science and analyzes genes related to the metabolic pathway of drugs.

It helps the doctor to choose the most appropriate medicine and the dosage for the best response of each patient.
In this way the highest possible efficiency of the treatment is achieved, significantly reducing the cost and the time of treatment and / or management of the disease/syndrome for the patient and the doctor.

The test analyzes the metabolic path of each patient for over 500 drugs related to simple and everyday diseases such as headaches, high blood pressure, etc. but also with difficult to manage diseases and disorders such as schizophrenia, depression, neurogenic disorders, etc.

MyTheragene® analyzes the effect of the drugs on the following fields:

  • Cardiology
  • Cardiology
  • Psychiatry
  • Oncology
  • Endocrinology
  • Gynecology
  • Gastroenterology
  • Immunology
  • Dermatology
  • Nephrology
  • Ophthalmology
  • Urology
  • Otolaryngology
  • Rheumatology
  • Hematology

MyTheragene® analysis is suitable for any person receiving or about to receive medication, but it is necessary for the following groups of patients:

• Patients with complex medication regimens and several health conditions
• Patients who show little or no response to current medication
• Patients who experience side effects from current treatment
• Patients with chronic diseases
• Patients with rare or severe disorders
• Patients with allergies to drugs

 

MyTheragene Genes Panel

ABCB1

ABCG2

ADRA2A

ANK1

APOE

COMT

CYP1A2

CYP2B6

CYP2C19

CYP2C8

CYP2C9

CYP2D6

CYP3A4

CYP3A5

DBH

DPYD

DRD1

DRD4

F2

F5

FLOT1

GABRA6

GABRP

GRIK4

HCP5

HLA-A

HTR2A

HTR2C

ITGB3

KIF6

MTHFR

OPRD1

OPRK1

OPRM1

SLCO1B1

TPMT

UGT1A1

UGT2B15

UGT2B7

VKORC1

The future is now

 

Many drugs already include pharmacogenomic information in the enclosed leaflets, highlighting the need to adapt prescriptions according to the individual's genetic profile.

The test is performed on blood or saliva and the result time is 10 working days.